CEL-SCI’s Chief Scientific Officer Discusses Cancer Immunotherapy Multikine

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE MKT: CVM) Chief Scientific Officer, Eyal Talor, Ph.D., spoke to Newswise LIVE recently to discuss the following:

• What is head and neck cancer? Can you provide us with a short overview?
• How are cancers in the head and neck region treated today? How difficult is the standard-of-care for these patients?
• Should there be a new shift in how head and neck cancer is treated?
• How does Multikine work in harnessing the patient’s immune system against cancer?
• A quick update on the Multikine trial.
• How will Multikine improve the lives and clinical outcome of patients?
• Where can more information be found on the Multikine trial?

The video is available on the Company’s website www.cel-sci.com/investor_relations.html.

A video webcast of CEL-SCI’s Chief Executive Officer, Geert Kersten, at the NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference from January 19, 2016 is also available on the Company’s website www.cel-sci.com/investor_relations.html.

About CEL-SCI Corporation

CEL-SCI is a Phase 3 immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. We believe that one must activate the immune system BEFORE radiation and chemotherapy, and even before surgery, to achieve the best results in the greatest number of patients. CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine (Leukocyte Interleukin Injection) for the treatment of head and neck cancer, which accounts for about 6% of cancers globally and a $6 billion market. Over 668 patients are already enrolled in this study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV infected patients with HPV related diseases. CEL-SCI has development partnerships with Teva Pharmaceuticals, Orient EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its own 75,000 sq. ft. manufacturing facility and produces Multikine for its clinical trials. When fully built out, this facility will have the capacity to supply about $3 billion worth of Multikine annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology as a potential vaccine for the treatment of rheumatoid arthritis.

The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.